Kymera Therapeutics, Inc. (KYMR)
119.41
+0.36
(+0.30%)
USD |
NASDAQ |
Sep 02, 14:34
Kymera Therapeutics Cash from Operations (Annual) : -232.89M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -232.89M |
| December 31, 2024 | -194.50M |
| December 31, 2023 | -102.83M |
| December 31, 2022 | -153.08M |
| Date | Value |
|---|---|
| December 31, 2021 | -128.95M |
| December 31, 2020 | 88.13M |
| December 31, 2019 | 17.90M |
| December 31, 2018 | -17.86M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 179.55M |
| Oncolytics Biotech, Inc. | -20.11M |
| Sangamo Therapeutics, Inc. | -97.21M |
| Sarepta Therapeutics, Inc. | -222.54M |
| Anixa Biosciences, Inc. | -7.173M |